ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the third quarter of 2014, including revenue from sales of Iclusig® (ponatinib). The Company also provided an update on corporate developments.
“Our third quarter results show solid growth in U.S. sales of Iclusig and continued commercial progress in Europe,” said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. “The EMA has adopted its final opinion on Iclusig following the Article 20 review in Europe, leaving the Iclusig indications unchanged, and we are now focused on obtaining pricing and reimbursement in all key European markets.
Help employers find you! Check out all the jobs and post your resume.
“Our third quarter results show solid growth in U.S. sales of Iclusig and continued commercial progress in Europe,” said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. “The EMA has adopted its final opinion on Iclusig following the Article 20 review in Europe, leaving the Iclusig indications unchanged, and we are now focused on obtaining pricing and reimbursement in all key European markets.
Help employers find you! Check out all the jobs and post your resume.
